Allarity Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on October 9, 2024, it received a formal notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq"). The notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq's Listing Rule 5550(a)(2) (the "Bid Price Rule"). Nasdaq noted that since September 11, 2024, Allarity's stock has maintained a closing bid price of $1.00 or more for 20 consecutive trading days, thereby meeting the requirements for regaining compliance with the Bid Price Rule.
Allarity Therapeutics, Inc.（"Allarity"或"公司"）（納斯達克：ALLR）是一家臨床階段的藥品公司，致力於開發個性化癌症治療。今天宣佈，截至2024年10月9日，收到納斯達克證券交易所（"納斯達克"）總法律顧問辦公室正式通知。通知確認公司已符合納斯達克交易所5550(a)(2)上市規則中規定的最低買盤價格要求（"買盤規則"）。納斯達克指出，自2024年9月11日以來，Allarity的股票已連續20個交易日維持收盤買盤價格爲1.00美元或更高，因此滿足了買盤規則的符合要求。
